The Biostatistics Shared Resource (BSR) of the Mayo Clinic Cancer Center (MCCC), under the leadership of Dr. Daniel Sargent, PhD (since 2001) has provided expert statistical collaboration with MCCC investigators for over 40 years for the development and conduct of peer-reviewed cancer center research encompassing basic science, clinical trials, epidemiologic research, and other translational and educational research. The primary usage of CCSG funds within the BSR is to support statistical collaboration on pilot projects, for assistance to investigators in developing approved research projects not otherwise funded but leading towards external funding, and to support unanticipated needs for statistical collaboration on MCCC approved projects. Funding is primarly provided to protect FTE of key faculty members to collaborate with MCCC members at no charge;funding is also provided to select senior MS statisticans for work on approved MCCC projects. In the current grant period the BSR has successfully and strategically firmly established high dimensional genomic and proteomic data analysis, and a robust presence at all 3 MCCC campuses. BSR faculty includes statistical methodological research leaders in clinical trial design, survival analysis, high-dimensional data, statistical genetics, quality of life research, and surrogate endpoints. The BSR has three focus areas (teams) tied together into a well-organized, efficient core. These are: (I) a Clinical Trials team responsible for cancer clinical trials, associated translational research, and patient and public education research projects, (11) a Population Science/Computational Genomics team responsible for statistical collaboration and data management support for high dimensional data analyses and cancer observational studies, including genetic and molecular epidemiology, and (III) a Quality of Life team responsible for collaboration, measurement tools, and analysis for MCCC investigators investigating the impact of clinical and psychosocial interventions on cancer patients, families, caregivers, and others. The BSR has been remarkably productive, with authorship on 833 peer reviewed publications and collaborations on 63 NIH or NIH-equivalent grants in the current grant period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682938
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$576,349
Indirect Cost
$214,152
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Bogenberger, James M; Delman, Devora; Hansen, Nanna et al. (2015) Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma 56:226-9
Sami, Sarmed S; Ragunath, Krish; Iyer, Prasad G (2015) Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol 13:623-34
Boland, Jennifer M; Wampfler, Jason A; Jang, Jin S et al. (2014) Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol 38:1681-8
Imperiale, Thomas F; Ransohoff, David F; Itzkowitz, Steven H et al. (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370:1287-97
Fackler, Mary Jo; Lopez Bujanda, Zoila; Umbricht, Christopher et al. (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74:2160-70
Porrata, Luis F; Ristow, Kay M; Habermann, Thomas M et al. (2014) Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 55:2728-38
Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43
Espejo, Rosario; Jeng, Yowjiun; Paulucci-Holthauzen, Adriana et al. (2014) PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity. J Cell Sci 127:497-508
Banck, Michaela S; Beutler, Andreas S (2014) Advances in small bowel neuroendocrine neoplasia. Curr Opin Gastroenterol 30:163-7

Showing the most recent 10 out of 340 publications